Press Release

Press Inquiries Contact
ICR
Revance@icrinc.com

16

September

2021

Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021

10

September

2021

Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

01

September

2021

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

05

August

2021

Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

29

July

2021

Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

26

May

2021

Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection